Amivantamab Injection Shows Promise for Resistant Head

What Did The Amivantamab Head And Neck Cancer Trial Find?

The pivotal OrigAMI-4 phase 1b/2 study evaluated subcutaneous amivantamab in 102 people with recurrent or metastatic head and neck squamous cell carcinoma after disease progression on an immune checkpoint inhibitor and platinum-based chemotherapy. According to the Journal of Clinical Oncology publication summarized by Yale School of Medicine, independent review found an objective response in 42% of participants, including complete tumor shrinkage in 15%.

Those numbers are notable because this is a population with few remaining options, and older salvage treatments such as paclitaxel or cetuximab have historically produced modest response rates. The median overall survival reported for the study was 12.5 months, but the trial was not randomized, so the results need confirmation against standard therapies before the drug can be treated as a new benchmark.

How Could A Bispecific Antibody Help Resistant Head And Neck Cancer?

Amivantamab is a bispecific antibody built to attach to two cancer-related targets: epidermal growth factor receptor, or EGFR, and MET. EGFR signaling has long been important in head and neck squamous cell carcinoma, while MET activation can contribute to tumor spread and treatment resistance, so a dual-target approach may help explain why the study generated interest at ASCO.

The drug also has immune-mediated effects: by marking tumor cells, it can help recruit immune mechanisms that kill malignant cells. That does not mean it works for everyone. Oncologists still need to weigh adverse effects, including skin reactions, infusion or injection-related reactions and less common lung inflammation risks seen with amivantamab, against a patient's symptoms, prior therapy and treatment goals.

What Should Patients Ask Before Considering This Treatment?

The most immediate relevance is for people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer has progressed after checkpoint immunotherapy and platinum chemotherapy. Patients can ask their oncology team whether their cancer's HPV or p16 status, prior treatment history and performance status match the population studied in OrigAMI-4, and whether any clinical trial or expanded-access route is appropriate.

For newly diagnosed disease, the evidence does not replace surgery, radiation, chemotherapy, immunotherapy or established targeted therapy strategies. A result like this is best viewed as a strong signal for a treatment pathway that may move into larger trials and regulatory review, not as a reason to delay proven care.